Methods for generating enucleated erythroid cells using pluripotent stem cells are provided. The methods permit the production of large numbers of cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Methods for generating megakaryocyte and platelets are also provided.

The invention relates to methods, peptides, nucleic acids and cells for use in isolating and expanding human T cell populations in an antigen-specific manner for immunodiagnostic or therapeutic purposes. The invention also relates to professional antigen presenting cells derived from pluripotent human stem cells, and to customizable antigen presentation by the antigen presenting cells.

Methods and compositions for differentiating pluripotent stem cells into cells of endothelial and hematopoietic lineages are disclosed.

A method of producing three-dimensional cellular tissues includes mixing stromal cells with a cationic substance, an extracellular matrix component and a polyelectrolyte to obtain a mixture; removing a liquid portion from the mixture to obtain a cell aggregate; culturing the cell aggregate in a medium to obtain a three-dimensional cellular tissue; and culturing the three-dimensional cellular tissue in a medium containing ascorbic acid and Transforming Growth Factor- (TGF-), wherein a thickness of the three-dimensional cellular tissue remains greater than 50 m for at least 3 days after culturing the three-dimensional cellular tissue in the medium containing ascorbic acid and TGF-.

There is provided a method of loading antigen in a dendritic cell for antigen presentation, the method comprising: modifying a pluripotent stem cell with a nucleic acid molecule encoding an antigen or one or more immunogenic epitopes thereof; inducing the pluripotent stem cell to differentiate into a dendritic cell that expresses and presents the antigen or the one or more immunogenic epitopes thereof. Dendritic cells, vaccines and methods of using the dendritic cells and vaccines are also provided.

The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCR cultured with stromal cells expressing Delta-like-1 or Delta-like-4, compositions prepared from such methods, and uses of thereof.

The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCR cultured with stromal cells expressing Delta-like-1 or Delta-like-4, compositions prepared from such methods, and uses of thereof.

We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.

Methods for generating enucleated erythroid cells using pluripotent stem cells are provided. The methods permit the production of large numbers of cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Methods for generating megakaryocyte and platelets are also provided.

Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1aCD5 or CD34+CD7+CD1aCD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.